Pharmacokinetics of standard versus high-dose isoniazid for treatment of multidrug-resistant tuberculosis.

Kamunkhwala Gausi Maxwell Tawanda ChirehwaElisa H IgnatiusRichard CourtXin SunLaura MoranRichard HafnerLubbe WiesnerSusan L RosenkranzVeronique de JagerNihal de VriesJoseph HardingTawanda GumboSusan SwindellsAndreas DiaconKelly E DooleyHelen McIlleronPaolo Denti

Published in: The Journal of antimicrobial chemotherapy (2022)

Markedly lower isoniazid exposures were observed in participants on combination MDR-TB treatment compared with monotherapy. Isoniazid displays saturable kinetics at doses >10 mg/kg. The safety implications of these phenomena remain unclear.

Keyphrases

mycobacterium tuberculosis
multidrug resistant
high dose
low dose
clinical trial
drug resistant
randomized controlled trial
escherichia coli
cystic fibrosis
acinetobacter baumannii
hiv aids
human immunodeficiency virus
drug induced